Top 5 in hemp derived CBD market, page-90

Bell Potter boosted target from 2.40 to 3.08.US He also raised earnings estimates for 2019 and 2020. Elixinol Global (EXL) Strong Revenue Growth Continues · Last week the 2018 Farm Bill House of Reps/Senate Conference Committee released its conference report which settled the final terms of the 2018 Farm Bill. The Bill has now been approved by both Houses of Congress and is due to go before President Trump for signing within the next few days. · The implications for the Hemp CBD industry are significant. The era of prohibition will end when the Bill is signed as Hemp will be permanently removed from Schedule 1 of the Controlled Substances Act. Hemp will be classified an agricultural product, therefore growers should be able to access crop insurance, water rights, US Department of Agriculture programs and a whole range of additional incentives. Interstate transport of hemp will no longer be illegal. · By implication, all federally regulated services including banking, merchant services and other services including advertising are now likely to begin to become available to the Hemp CBD industry. As we have stated for many months, the legalisation of the cultivation of hemp is a potential game changer of the Hemp CBD industry. This is an important step towards these products becoming available in mainstream retail across the country. Elixinol branded products are only available at this time via the company’s ecommerce platform. · The US FDA has not modified its position on safety of Hemp CBD products as either a food or dietary supplement. Nevertheless the market for these products continues to expand rapidly and the cultivation of the crop from which Hemp CBD is derived is about to be legalised. Based on these observations the FDA may reconsider its position. The reality is that the FDA has not taken enforcement action against Hemp CBD products marketed as dietary supplements. Earnings Upgrades · FY18 EPS is upgrades by 0.3cps. FY19 and FY20 EPS are upgraded by 16% and 9% respectively. Valuation is raised to $3.08 and we retain our Buy recommendation.